 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 January 1995 | Volume 122 Issue 2 | Pages 133-141
Purpose: To compare and contrast the effects of antihypertensive agents on serum lipids and blood pressure in different patient populations.
Data Sources: A MEDLINE search and bibliographies from recent comprehensive reviews were used to identify trials that provided sufficient data to calculate the change in one or more serum lipid values measured before and after antihypertensive therapy.
Study Selection: 474 controlled and uncontrolled clinical trials investigated the effects of 85 antihypertensive agents on lipids and blood pressure in more than 65 000 patients.
Data Extraction: Data on triglyceride and total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol levels; blood pressure; patient characteristics; and study design.
Data Synthesis: Differences in the effects of agents, adjusted for differences in patient populations and study design, were examined using multiple linear regression analysis that was weighted by study quality and inverse variance. Diuretics caused relative increases in cholesterol levels (regression coefficient = 0.13 mmol/L; 95% CI, 0.09 to 0.18 mmol/L) that were greater with higher doses (additional effect of high dose, 0.12 mmol/L; CI, 0.04 to 0.20 mmol/L) and were worse in blacks than in nonblacks (additional effect in blacks, 0.13 mmol/L; CI, 0.01 to 0.26 mmol/L). ß-blockers caused increases in triglyceride levels (0.35 mmol/L; CI, 0.31 to 0.39 mmol/L) that were substantially smaller for agents with intrinsic sympathomimetic activity (amelioration of ß-blocker increase, –0.21 mmol/L; CI, –0.27 to –0.16 mmol/L). When combined with cardioselectivity, ß-blockers with intrinsic sympathomimetic activity favorably affected lipids and reduced both total ( –0.14 mmol/L; CI, –0.24 to –0.04 mmol/L) and LDL cholesterol levels ( –0.17 mmol/L; CI, –0.28 to –0.07 mmol/L).
Conclusion: With the exception of calcium antagonists, nearly all antihypertensive agents affect serum lipids. These effects differ among patient populations.
Author and Article Information
From the University of Minnesota College of Medicine and Hennepin County Medical Center, Minneapolis, Minnesota.
REVIEW
Effects of Antihypertensive Therapy on Serum Lipids
-Blockers beneficially affected total cholesterol ( –0.23 mmol/L; CI, –0.28 to –0.18 mmol/L), LDL cholesterol ( –0.20 mmol/L; CI, –0.25 to –0.15 mmol/L), triglycerides ( –0.07 mmol/L; CI, –0.11 to –0.03 mmol/L), and, in younger persons, HDL cholesterol (0.02 mmol/L; 0.01 to 0.04 mmol/L). Converting enzyme inhibitors reduced triglycerides ( –0.07 mmol/L; CI, –0.12 to –0.02 mmol/L), and, in patients with diabetes, total cholesterol ( –0.22 mmol/L; CI, –0.34 to –0.10 mmol/L). Vasodilators reduced total ( –0.22 mmol/l; CI, –0.30 to –0.10 mmol/L) and LDL cholesterol ( –0.22 mmol/L; CI, –0.29 to –0.11 mmol/L) and increased HDL cholesterol (0.06 mmol/L; CI, 0.02 to 0.09 mmol/L).
Requests for Reprints: Bertram L. Kasiske, MD, Department of Medicine, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415.
Acknowledgment: The authors thank Ms. Jan Lovick and Ms. Anita Goth for their help in preparing the manuscript. A list of the studies included in the meta-analysis is available on request.
This article has been cited by other articles:
|
|
 |
|
  F. H. Messerli, S. Bangalore, and S. Julius Risk/Benefit Assessment of {beta}-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension Circulation, May 20, 2008; 117(20): 2706 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sipahi, E. M. Tuzcu, K. E. Wolski, S. J. Nicholls, P. Schoenhagen, B. Hu, C. Balog, M. Shishehbor, W. A. Magyar, T. D. Crowe, et al. {beta}-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials Ann Intern Med, July 3, 2007; 147(1): 10 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Tsouli, E. N. Liberopoulos, D. N. Kiortsis, D. P. Mikhailidis, and M. S. Elisaf Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 1 - 15. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Fallo, F. Veglio, C. Bertello, N. Sonino, P. Della Mea, M. Ermani, F. Rabbia, G. Federspil, and P. Mulatero Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 454 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Hopkins, L. L. Wu, S. C. Hunt, and E. A. Brinton Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1003 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Rajaratnam, H. Gylling, and T. A. Miettinen Cholesterol Absorption, Synthesis, and Fecal Output in Postmenopausal Women With and Without Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., October 1, 2001; 21(10): 1650 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Grossman, F. H. Messerli, and J. M. Neutel Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors? Arch Intern Med, July 10, 2000; 160(13): 1905 - 1911. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Golomb and M. H. Criqui Antihypertensives: Much Ado About Lipids Arch Intern Med, March 22, 1999; 159(6): 535 - 537. [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Chrysant Fixed Low-Dose Drug Combination for the Treatment of Hypertension Arch Fam Med, July 1, 1998; 7(4): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Messerli, E. Grossman, and U. Goldbourt Are {beta}-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?: A Systematic Review JAMA, June 17, 1998; 279(23): 1903 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Lisi and S. Dagogo-Jack Troglitazone: Monotherapy Indication Arch Intern Med, February 23, 1998; 158(4): 412 - 412. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hayashi, M. Gohda, S. Matzno, Y. Kubo, H. Kido, T. Yamauchi, and N. Nakamura Possible Mechanism of Action of AE0047, a Calcium Antagonist, on Triglyceride Metabolism J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 882 - 890. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Byyny, T. Shannon, L. A. Schwartz, C. Rotolo, and S. Jungerwirth Efficacy and Safety of Nifedipine Coat-Core versus Amlodipine in Patients With Mild to Moderate Essential Hypertension: Comparison of 24-Hour Mean Ambulatory Diastolic Blood Pressure Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(2): 77 - 83. [Abstract] [PDF]
|
|
Article
